249 related articles for article (PubMed ID: 34275161)
21. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
[TBL] [Abstract][Full Text] [Related]
22. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus.
Fitzgerald RC; di Pietro M; Ragunath K; Ang Y; Kang JY; Watson P; Trudgill N; Patel P; Kaye PV; Sanders S; O'Donovan M; Bird-Lieberman E; Bhandari P; Jankowski JA; Attwood S; Parsons SL; Loft D; Lagergren J; Moayyedi P; Lyratzopoulos G; de Caestecker J;
Gut; 2014 Jan; 63(1):7-42. PubMed ID: 24165758
[TBL] [Abstract][Full Text] [Related]
23. A deep learning system for detection of early Barrett's neoplasia: a model development and validation study.
Fockens KN; Jong MR; Jukema JB; Boers TGW; Kusters CHJ; van der Putten JA; Pouw RE; Duits LC; Montazeri NSM; van Munster SN; Weusten BLAM; Alvarez Herrero L; Houben MHMG; Nagengast WB; Westerhof J; Alkhalaf A; Mallant-Hent RC; Scholten P; Ragunath K; Seewald S; Elbe P; Baldaque-Silva F; Barret M; Ortiz Fernández-Sordo J; Villarejo GM; Pech O; Beyna T; van der Sommen F; de With PH; de Groof AJ; Bergman JJ;
Lancet Digit Health; 2023 Dec; 5(12):e905-e916. PubMed ID: 38000874
[TBL] [Abstract][Full Text] [Related]
24. A majority of patients with Barrett's oesophagus are unlikely to benefit from endoscopic cancer surveillance.
Gudlaugsdottir S; van Blankenstein M; Dees J; Wilson JH
Eur J Gastroenterol Hepatol; 2001 Jun; 13(6):639-45. PubMed ID: 11434588
[TBL] [Abstract][Full Text] [Related]
25. A predictive Bayesian network that risk stratifies patients undergoing Barrett's surveillance for personalized risk of developing malignancy.
Bradley A; Sami S; N G H; Macleod A; Prasanth M; Zafar M; Hemadasa N; Neagle G; Rosindell I; Apollos J
PLoS One; 2020; 15(10):e0240620. PubMed ID: 33045017
[TBL] [Abstract][Full Text] [Related]
26. Barrett's oesophagus: epidemiology, cancer risk and implications for management.
de Jonge PJ; van Blankenstein M; Grady WM; Kuipers EJ
Gut; 2014 Jan; 63(1):191-202. PubMed ID: 24092861
[TBL] [Abstract][Full Text] [Related]
27. Malignant Barrett's oesophagus.
Li H
Eur J Cancer Prev; 1993 Jan; 2(1):47-52. PubMed ID: 8428176
[TBL] [Abstract][Full Text] [Related]
28. Incidence of Barrett's adenocarcinoma in an Italian population: an endoscopic surveillance programme. Gruppo Operativo per lo Studio delle Precancerosi Esofagee (GOSPE).
Ferraris R; Bonelli L; Conio M; Fracchia M; Lapertosa G; Aste H
Eur J Gastroenterol Hepatol; 1997 Sep; 9(9):881-5. PubMed ID: 9355787
[TBL] [Abstract][Full Text] [Related]
29. Barrett's oesophagus: epidemiology, diagnosis and clinical management.
Whiteman DC; Kendall BJ
Med J Aust; 2016 Oct; 205(7):317-24. PubMed ID: 27681974
[TBL] [Abstract][Full Text] [Related]
30. Comparison of methylene blue-directed biopsies and four-quadrant biopsies in the detection of high-grade intraepithelial neoplasia and early cancer in Barrett's oesophagus.
Gossner L; Pech O; May A; Vieth M; Stolte M; Ell C
Dig Liver Dis; 2006 Oct; 38(10):724-9. PubMed ID: 16911879
[TBL] [Abstract][Full Text] [Related]
31. Esophageal adenocarcinoma in a first-degree relative increases risk for esophageal adenocarcinoma in patients with Barrett's esophagus.
Tofani CJ; Gandhi K; Spataro J; Yoo J; Murphy M; Mohan N; Daitch Z; Shah A; Janowski R; Huntley C; Dabbish N; Keith S; Coben R; Cohen S; Kastenberg D; Infantolino A
United European Gastroenterol J; 2019 Mar; 7(2):225-229. PubMed ID: 31080607
[TBL] [Abstract][Full Text] [Related]
32. Outcome of esophageal adenocarcinoma detected during endoscopic biopsy surveillance for Barrett's esophagus.
Incarbone R; Bonavina L; Saino G; Bona D; Peracchia A
Surg Endosc; 2002 Feb; 16(2):263-6. PubMed ID: 11967675
[TBL] [Abstract][Full Text] [Related]
33. Barrett's oesophagus: frequency and prediction of dysplasia and cancer.
Falk GW
Best Pract Res Clin Gastroenterol; 2015 Feb; 29(1):125-38. PubMed ID: 25743461
[TBL] [Abstract][Full Text] [Related]
34. Barrett's oesophagus: optimal strategies for prevention and treatment.
Fass R; Sampliner RE
Drugs; 2003; 63(6):555-64. PubMed ID: 12656653
[TBL] [Abstract][Full Text] [Related]
35. Systematic review with meta-analysis: prevalence of prior and concurrent Barrett's oesophagus in oesophageal adenocarcinoma patients.
Tan MC; Mansour N; White DL; Sisson A; El-Serag HB; Thrift AP
Aliment Pharmacol Ther; 2020 Jul; 52(1):20-36. PubMed ID: 32452599
[TBL] [Abstract][Full Text] [Related]
36. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota.
Conio M; Cameron AJ; Romero Y; Branch CD; Schleck CD; Burgart LJ; Zinsmeister AR; Melton LJ; Locke GR
Gut; 2001 Mar; 48(3):304-9. PubMed ID: 11171817
[TBL] [Abstract][Full Text] [Related]
37. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus.
Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
Med J Aust; 2004 Apr; 180(8):387-91. PubMed ID: 15089728
[TBL] [Abstract][Full Text] [Related]
38. Barrett's oesophagus: a review of costs of the illness.
Arguedas MR; Eloubeidi MA
Pharmacoeconomics; 2001; 19(10):1003-11. PubMed ID: 11735670
[TBL] [Abstract][Full Text] [Related]
39. Surveillance for Barrett's oesophagus: results from a programme in Northern Ireland.
Murphy SJ; Dickey W; Hughes D; O'Connor FA
Eur J Gastroenterol Hepatol; 2005 Oct; 17(10):1029-35. PubMed ID: 16148547
[TBL] [Abstract][Full Text] [Related]
40. Meta analysis: Cancer risk in Barrett's oesophagus.
Thomas T; Abrams KR; De Caestecker JS; Robinson RJ
Aliment Pharmacol Ther; 2007 Dec; 26(11-12):1465-77. PubMed ID: 17900269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
